Literature DB >> 16079122

Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes.

Alfredo Molteni, Annamaria Nosari, Marco Montillo, Anna Cafro, Catherine Klersy, Enrica Morra.   

Abstract

We report on febrile episodes occurring among 379 patients affected by chronic lymphocytic leukemia, observed from 1984 to 2002. One hundred and twenty eight patients (33.7%) developed 341 febrile episodes, of which 251 were documented infections (82 severe and 169 moderate). Among various risk factors, only previous treatment with multiple regimens of chemotherapy was associated with severity of infection (p=0.0005).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16079122

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

1.  Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

Authors:  Xavier C Badoux; Michael J Keating; Xuemei Wang; Susan M O'Brien; Alessandra Ferrajoli; Stefan Faderl; Jan Burger; Charles Koller; Susan Lerner; Hagop Kantarjian; William G Wierda
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

2.  Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.

Authors:  Marcin Pasiarski; Jacek Rolinski; Ewelina Grywalska; Agnieszka Stelmach-Goldys; Izabela Korona-Glowniak; Stanislaw Gozdz; Iwona Hus; Anna Malm
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

3.  Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes.

Authors:  Firas El Chaer; Dimpy P Shah; Joumana Kmeid; Ella J Ariza-Heredia; Chitra M Hosing; Victor E Mulanovich; Roy F Chemaly
Journal:  Cancer       Date:  2017-02-08       Impact factor: 6.860

4.  Infectious complications in chronic lymphocytic leukemia.

Authors:  Annamaria Nosari
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-11-05       Impact factor: 2.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.